Key points: The combination of lenalidomide and rituximab is highly effective in patients with CLL and low baseline Beta2-microglobulin levels. Mutations in the NOTCH signaling pathway are associated with worse outcome in patients with CLL treated with lenalidomide and rituximab.
Home / Resource Library / Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL